Ana Plata bello

Dr. Ana Plata bello


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAna Plata bello
Ana Plata bello
Félix Guerrero-RamosFélix Guerrero-Ramos
Félix Guerrero-Ramos
CGCarlos Garcia
Carlos Garcia
AGAlejandro González-Díaz
Alejandro González-Díaz
IGIgnacio Gonzalez-Valcárcel
Ignacio Gonzalez-Valcárcel
Javier C. AnguloJavier C. Angulo
Javier C. Angulo
(1) Background: Intravesical mitomycin-C (MMC) combined with hyperthermia is increasingly used in non-muscle invasive bladder cancer (NMIBC), especially in the context of a relative BCG shortage. We aim to determine real-world data on the long-term treatment outcomes of adjunct hyperthermic intravesical chemotherapy (HIVEC) with MMC and a COMBAT® bladder recirculation system (BRS); (2) Methods: A prospective observational trial was performed on patients with NMIBC treated with HIVEC using BRS in nine academic institutions in Spain between 2012–2020 (HIVEC-E). Treatment effectiveness (recurrence, progression and overall mortality) was evaluated in patients treated with HIVEC MMC 40mg in the adjuvant setting, with baseline data and a clinical follow-up, that comprise the Full Analysis Set (FAS). Safety, according to the number and severity of adverse effects (AEs), was evaluated in the safety (SAF) population, composed by patients with at least one adjunct HIVEC MMC instillation; (3) Results: The FAS population (n = 502) received a median number of 8.78 ± 3.28 (range 1–20) HIVEC MMC instillations. The median follow-up duration was 24.5 ± 16.5 (range 1–81) months. Its distribution, based on EAU risk stratification, was 297 (59.2%) for intermediate and 205 (40.8%) for high-risk. The figures for five-year recurrence-free and progression-free survival were 50.37% (53.3% for intermediate and 47.14% for high-risk) and 89.83% (94.02% for intermediate and 84.23% for high-risk), respectively. A multivariate analysis identified recurrent tumors (HR 1.83), the duration of adjuvant HIVEC therapy <4 months (HR 1.72) and that high-risk group (HR 1.47) were at an increased risk of recurrence. Independent factors of progression were high-risk (HR 3.89), recurrent tumors (HR 3.32) and the induction of HIVEC therapy without maintenance (HR 2.37). The overall survival was determined by patient age at diagnosis (HR 3.36) and the treatment duration (HR 1.82). The SAF population (n = 592) revealed 406 (68.58%) patients without AEs and 186 (31.42%) with at least one AE: 170 (28.72%) of grade 1–2 and 16 (2.7%) of grade 3–4. The most frequent AEs were dysuria (10%), pain (7.1%), urgency (5.7%), skin rash (4.9%), spasms (3.7%) and hematuria (3.6%); (4) Conclusions: HIVEC using BRS is efficacious and well tolerated. A longer treatment duration, its use in naïve patients and the intermediate-risk disease are independent determinants of success. Furthermore, a monthly maintenance of adjunct MMC HIVEC diminishes the progression rate of NMIBC.

1 March 2022
Verified
Journal Article
Closed access
ABAna Plata bello
Ana Plata bello
MJMarco Antonio Tamayo Jover
Marco Antonio Tamayo Jover
FNFernando Gutierrez Nicolas
Fernando Gutierrez Nicolas
SLSilvia Acosta Lopez
Silvia Acosta Lopez
TMTomas Concepcion Masip
Tomas Concepcion Masip
JBJulio Plata Bello
Julio Plata Bello

18 September 2021
Verified
Conference Paper
Closed access
TPTayda Placeres-Hernández
Tayda Placeres-Hernández
ABAna Plata bello
Ana Plata bello
MNMiguel Ángel Navarro-Galmes
Miguel Ángel Navarro-Galmes
NCNicolás Fernández Cranz
Nicolás Fernández Cranz
LGLorenzo Giunco
Lorenzo Giunco
TMTomás Concepción Masip
Tomás Concepción Masip
Background and objetives: Androgen deprivation therapy (ADT) is an essential coadjuvant therapy in some PC patients. Although ADT has been associ |

15 December 2022 in European Urology
Verified
Journal Article
Closed access
ABAna Plata bello
Ana Plata bello
KTKarim Touijer
Karim Touijer